Pacira BioSciences Newsroom

VectorY Strengthens Leadership Team With Appointment of Jim Scibetta as New CEO

BusinesswireDec 16 20:00

Express News | Doma Perpetual: Urges Pacira to Immediately Commence Stock Tender Offer for 10 Mln Shares Using Its Substantial Cash on Hand

BreakingsDec 11 21:06

Express News | Doma Perpetual: Believes Pacira Biosciences' Stock Is "Grossly Undervalued"

BreakingsDec 11 21:06

Express News | Doma Perpetual Capital Management Announces Intent to Nominate Four Highly Qualified, Independent Director Candidates at 2025 Annual Meeting of Pacira Biosciences, Inc.

BreakingsDec 11 21:05

DOMA Perpetual Capital Management Announces Intent to Nominate Four Highly Qualified, Independent Director Candidates at 2025 Annual Meeting of Pacira BioSciences, Inc.

PR NewswireDec 11 21:05

Pacira BioSciences (NASDAQ:PCRX) Shareholders Are up 7.2% This Past Week, but Still in the Red Over the Last Three Years

Simply Wall StDec 11 03:28

Press Release: Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Dow JonesDec 6 21:00

Express News | Pacira Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

BreakingsDec 6 21:00

H.C. Wainwright Maintains Pacira BioSciences(PCRX.US) With Buy Rating, Maintains Target Price $39

Futu NewsDec 6 00:35 · Ratings

PCRX Receives New Patent for Lead Pain Drug Exparel in the US

Zacks Dec 5 00:30

Decoding 6 Analyst Evaluations For Pacira BioSciences

BenzingaDec 4 20:00

HC Wainwright & Co. Reiterates Buy on Pacira BioSciences, Maintains $39 Price Target

BenzingaDec 4 19:28 · Ratings

Express News | Pacira Biosciences Inc: Awarded New U.S. Patent Covering Exparel Composition; Provides Protection Into 2044

BreakingsDec 3 20:32

US Manufacturing Index Rises To 43, Highest Since 2020

Business TodayNov 16 15:13

Express News | Pacira Biosciences Inc - No Serious Treatment-Emergent Adverse Events Reported

BreakingsNov 14 23:05

Express News | Pacira Biosciences Inc - Phase 1 Trial Shows Safety and Efficacy of Pcrx-201

BreakingsNov 14 23:05

Express News | Pacira Announces 104-Week Safety and Efficacy Data Following Local Administration of Pcrx-201 for Moderate to Severe Osteoarthritis of the Knee

BreakingsNov 14 23:05

Pacira BioSciences Insider Lowered Holding By 85% During Last Year

Simply Wall StNov 14 18:30

Pacira Announces 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee

Pacira BioSciencesNov 14 13:00

Pacira BioSciences Price Target Cut to $17.00/Share From $25.00 by Barclays

Dow JonesNov 12 23:13 · Ratings